TREACE MEDICAL CONCEPTS INC (TMCI)

US89455T1097 - Common Stock

7.79  -0.11 (-1.39%)

After market: 7.79 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TMCI. TMCI was compared to 187 industry peers in the Health Care Equipment & Supplies industry. TMCI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TMCI is valued expensive at the moment.



2

1. Profitability

1.1 Basic Checks

In the past year TMCI has reported negative net income.
In the past year TMCI has reported a negative cash flow from operations.
TMCI had negative earnings in each of the past 5 years.
TMCI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

TMCI has a Return On Assets (-28.89%) which is in line with its industry peers.
With a Return On Equity value of -58.65%, TMCI perfoms like the industry average, outperforming 45.70% of the companies in the same industry.
Industry RankSector Rank
ROA -28.89%
ROE -58.65%
ROIC N/A
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TMCI has a better Gross Margin (80.61%) than 93.01% of its industry peers.
In the last couple of years the Gross Margin of TMCI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TMCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TMCI has more shares outstanding
The debt/assets ratio for TMCI has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 2.15 indicates that TMCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.15, TMCI is in the better half of the industry, outperforming 60.75% of the companies in the same industry.
TMCI has a Debt/Equity ratio of 0.51. This is a neutral value indicating TMCI is somewhat dependend on debt financing.
TMCI has a worse Debt to Equity ratio (0.51) than 62.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z 2.15
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

TMCI has a Current Ratio of 4.12. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TMCI (4.12) is better than 70.97% of its industry peers.
A Quick Ratio of 2.98 indicates that TMCI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.98, TMCI is in the better half of the industry, outperforming 64.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 2.98

5

3. Growth

3.1 Past

The earnings per share for TMCI have decreased strongly by -18.99% in the last year.
The Revenue has grown by 16.13% in the past year. This is quite good.
TMCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.27% yearly.
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Sales Q2Q%10.62%

3.2 Future

Based on estimates for the next years, TMCI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.00% on average per year.
Based on estimates for the next years, TMCI will show a quite strong growth in Revenue. The Revenue will grow by 14.06% on average per year.
EPS Next Y-16.48%
EPS Next 2Y2.64%
EPS Next 3Y4.58%
EPS Next 5Y11%
Revenue Next Year12.03%
Revenue Next 2Y10.18%
Revenue Next 3Y9.96%
Revenue Next 5Y14.06%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TMCI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.64%
EPS Next 3Y4.58%

0

5. Dividend

5.1 Amount

No dividends for TMCI!.
Industry RankSector Rank
Dividend Yield N/A

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (1/6/2025, 4:30:01 PM)

After market: 7.79 0 (0%)

7.79

-0.11 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)N/A N/A
Inst Owners64.06%
Inst Owner Change0%
Ins Owners23.17%
Ins Owner Change8.75%
Market Cap485.32M
Analysts72.31
Price Target7.88 (1.16%)
Short Float %5.19%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.87%
Min EPS beat(2)1.96%
Max EPS beat(2)9.78%
EPS beat(4)3
Avg EPS beat(4)0.98%
Min EPS beat(4)-10.69%
Max EPS beat(4)9.78%
EPS beat(8)6
Avg EPS beat(8)7.74%
EPS beat(12)8
Avg EPS beat(12)-182.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.5%
Min Revenue beat(2)1.36%
Max Revenue beat(2)1.65%
Revenue beat(4)4
Avg Revenue beat(4)1.46%
Min Revenue beat(4)0.73%
Max Revenue beat(4)2.12%
Revenue beat(8)7
Avg Revenue beat(8)2%
Revenue beat(12)11
Avg Revenue beat(12)3.12%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.75%
PT rev (3m)6.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.63%
EPS NY rev (1m)0%
EPS NY rev (3m)1.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.39
P/FCF N/A
P/OCF N/A
P/B 4.63
P/tB 5.79
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS3.26
BVpS1.68
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.89%
ROE -58.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.61%
FCFM N/A
ROA(3y)-20.43%
ROA(5y)-17.61%
ROE(3y)-42.96%
ROE(5y)-163.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.25%
GM growth 5YN/A
F-Score2
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 135.37%
Cap/Sales 5.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 2.98
Altman-Z 2.15
F-Score2
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)434.52%
Cap/Depr(5y)309.03%
Cap/Sales(3y)6.49%
Cap/Sales(5y)4.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.71%
EPS Next Y-16.48%
EPS Next 2Y2.64%
EPS Next 3Y4.58%
EPS Next 5Y11%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y48.28%
Revenue growth 5YN/A
Sales Q2Q%10.62%
Revenue Next Year12.03%
Revenue Next 2Y10.18%
Revenue Next 3Y9.96%
Revenue Next 5Y14.06%
EBIT growth 1Y-29.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.91%
EBIT Next 3Y27.83%
EBIT Next 5Y21.79%
FCF growth 1Y-1.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.66%
OCF growth 3YN/A
OCF growth 5YN/A